Onkologia Medikoa
Espezialitatea
Complexo Hospitalario Universitario de Santiago
Santiago de Compostela, EspañaComplexo Hospitalario Universitario de Santiago-ko ikertzaileekin lankidetzan egindako argitalpenak (14)
2024
2023
2022
-
Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial
Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661
2021
-
Electronic health records and patient registries in medical oncology departments in Spain
Clinical and Translational Oncology, Vol. 23, Núm. 10, pp. 2099-2108
-
First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met
European Journal of Cancer, Vol. 159, pp. 174-181
2020
2019
-
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132
2018
-
Final results of RENO study: Randomized phase II of oral vinorelbine or etoposide with cisplatin & chemo-radiation in stage III NSCLC - SLCG 10/02
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii490
2017
-
A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01)
European Urology Focus, Vol. 3, Núm. 4-5, pp. 430-436
2016
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
-
Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: A retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study
Melanoma Research, Vol. 26, Núm. 3, pp. 278-283
-
Validation of the international metastatic renal-cell carcinoma database consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: The Spanish oncologic genitourinary group (SOGUG) SPAZO study
Annals of Oncology, Vol. 27, Núm. 4, pp. 706-711
2003
-
Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer
Lung Cancer, Vol. 39, Núm. 1, pp. 77-84
2002
-
Predictive value of P53, BCL-2, and BAX in advanced head and neck carcinoma
American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 25, Núm. 6, pp. 588-590